Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
Kurata
T
T
Tamura
K
K
Kaneda
H
H
Nogami
T
T
Uejima
H
H
Asai Go
G o
Go
Nakagawa
K
K
Fukuoka
M
M
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000187:drug effects; D000077156:Gefitinib; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009364:Neoplasm Recurrence, Local; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000008:administration & dosage; D019233:Retreatment; D043823:Taxoids / Q000008:administration & dosage
D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; D000077146:Irinotecan; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib; D002166:Camptothecin